Acarbose therapy as prevention of multiple cardiovascular risk factors of metabolic syndrome
https://doi.org/10.18705/1607-419X-2003-9-2-51-54
Abstract
The metabolic syndrome is a state that precedes the development of atherosclerosis, type 2 diabetes mellitus, and arterial hypertension (AH) Timely adequate treatment may prevent the development and progression of these diseases that are main causes of higher death rates Peripheral acting drugs should be preferred for patients at high cardiovascular risk Acarbose is one of these drugs It prevents carbohydrates from being absorbed in the small bowel The results of our use of acarbose have shown its high efficacy Acarbose therapy significantly decreases body weight, postprandial glucose levels, glycated hemoglobin, and blood pressure Acarbose may be used as monotherapy in patients with the metabolic syndrome and mild AH
About the Authors
V. B. Mychka
Институт клинической кардиологии им. А.Л.Мясникова; Российский кардиологический научно-производственный комплекс Минздрава РФ
Russian Federation
Russian Federation
R. M. Bogiyeva
Институт клинической кардиологии им. А.Л.Мясникова; Российский кардиологический научно-производственный комплекс Минздрава РФ
Russian Federation
Russian Federation
K. M. Mamyrbayeva
Институт клинической кардиологии им. А.Л.Мясникова; Российский кардиологический научно-производственный комплекс Минздрава РФ
Russian Federation
Russian Federation
I. Ye. Chazova
Институт клинической кардиологии им. А.Л.Мясникова; Российский кардиологический научно-производственный комплекс Минздрава РФ
Russian Federation
Russian Federation
References
1. Muscelli Е, Emdin М, Natali A et al. Cardiac responses to insulin in vivo influence of obesity J Clm Endocrinol Metab 1998, 83 2084-90
2. Anderson EA, Hoffinan RP, Balon TW et al. Hypennsulinemia produces both sympathetic neuronal activation and vasodilatation in normal humans J Clin Invest 1991, 876 2246-52
3. Lembo G, Napoli R, Capaldo B et al. Abnormal sympathetic overactwity evoked by insulin m the skeletal muscle of patients with essential hypertension J Clin Invest 1992,90 24-9
4. Davis SN, Colburn C, Robbins R et al. Evidence that the brain of the conscious dog is insulin sensitive J Clin Invest 1995,95 593-602
5. Schwartz MW, Figlewicz DP, Baskin DB et al. Insulin in the bram a hormonal regulator of energy balance EndocrRev 1992, 13 81-113
6. Ferrannmi E, Seghien G, Muscelli E Insulin and the rennin -angeotensm-aldos terone system influence of ACE inhibition J Cardiovasc Pharmacol 1994, 24 (suppl 3) S61-S80
7. Wassertheil-Smoller S, Oberman Ą Blaufox MD et al. The trial of antihypertensive ineterventions and management (TAIM) study Final results to blood pressure, cardiovascular risk, and quality of life Am J Hypertens 1992,5 37-44
8. Gnmm RH, Grandits GA, Culter JA et al. Relatmnship of quality of life measures— to long-term lifestyle and drug treatment in the treatment of mild hypertension study (TOMHS) Arch Intem Med 1997, 157 638-48
9. Chiasson J et al. The STOP-NIDDM tnal An international study on efficacy of an a-glucosidase inhibitor to prevent type 2 diabetes in a population with IGT Diabetes Care 1998, 21 1720-5
Review
For citations:
Mychka V.B., Bogiyeva R.M., Mamyrbayeva K.M., Chazova I.Ye. Acarbose therapy as prevention of multiple cardiovascular risk factors of metabolic syndrome. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2003;9(2):51-54. (In Russ.) https://doi.org/10.18705/1607-419X-2003-9-2-51-54
Views:
829
Email this article 